Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer

(MedPage Today) -- WASHINGTON -- Treatment with cretostimogene grenadenorepvec, an investigational intravesically delivered oncolytic immunotherapy, achieved high response rates in patients with high-risk non-muscle-invasive bladder cancer (NMIBC...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news